Loading...
Loading...
TTOO| Name | Value |
|---|---|
| Revenues | 1,952.0K |
| Cost of Revenue | 2,693.0K |
| Gross Profit | -741.0K |
| Operating Expense | 8,834.0K |
| Operating I/L | -9,575.0K |
| Other Income/Expense | 332.0K |
| Interest Income | 0.0K |
| Pretax | -9,243.0K |
| Income Tax Expense | -64.0K |
| Net Income/Loss | -9,243.0K |
T2 Biosystems, Inc. is an in vitro diagnostics company that develops and commercializes diagnostic products and product candidates globally. The company's technology allows for the detection of pathogens, biomarkers, and abnormalities in various patient sample types. Its product portfolio includes the T2Dx Instrument, T2Candida, T2Bacteria, T2Resistance, T2SARS-CoV-2 panel, T2Biothreat, comprehensive sepsis panel, T2Cauris, and T2Lyme. These products enable the direct detection of various infections and antibiotic resistance markers, providing healthcare professionals with rapid and accurate diagnostic information. T2 Biosystems generates revenue through the sale of its diagnostic instruments and test panels, as well as through collaboration agreements with other companies.
